FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1447263> ?p ?o ?g. }

• W1447263 abstract "Hepatic fibrosis is characterized by intense tissue remodeling. In this study, we assessed whether CO3-610, a new identified neoepitope, could be used as a surrogate biomarker of liver fibrosis and portal hypertension in CCl4-induced experimental fibrosis. Serum CO3-610 was measured by ELISA. Liver fibrosis was quantified by Sirius red staining. Serum hyaluronic acid (HA) was measured with a binding-protein assay. Gene expression of collagens I and III, MMP2 and MMP9, and tissue inhibitors of matrix metalloproteinase 1 and 2 was quantified by PCR. Hemodynamic measurements were taken in a subgroup of animals. A close direct relationship was found between serum CO3-610 and hepatic collagen content (r= 0.78; P<0.001), superior to that found for serum HA (r= 0.49; P<0.05). CO3-610 levels in rats with severe fibrosis (43.5±3.3 ng/mL, P<0.001) and cirrhosis (60.6±4.3 ng/mL, P<0.001) were significantly higher than those in control animals (26.6±1.3 ng/mL). Importantly, a highly significant relationship was found between serum CO3-610 and portal hypertension (r= 0.84; P<0.001). Liver MMP9 expression increased significantly in fibrotic animals but decreased to control levels in cirrhotic ones. Circulating CO3-610 behaves as a reliable indicator of hepatic remodeling and portal hypertension in experimental fibrosis. Therefore, this peptide could ultimately be a useful marker for the management of liver disease in patients. Endocannabinoids behave as antifibrogenic agents by interacting with cannabinoid CB2 receptors, whereas the apelin (AP) system acts as a proangiogenic and profibrogenic mediator in the liver. This study assessed the effect of long-term stimulation of CB2 receptors or AP receptor (APJ) blockade on fibrosis progression in rats under a non-discontinued fibrosis induction program. The study was performed in control and CCl4-treated rats for 13 weeks. Fibrosis-induced rats received a CB2 receptor agonist (AM1241) (1 mg/kg), an APJ antagonist (F13A) (75 ?g/kg), or vehicle daily during the last 5 weeks of the CCl4 inhalation program. Mean arterial pressure (MAP), portal pressure (PP), hepatic collagen content, angiogenesis, cell infiltrate, and mRNA expression of a panel of fibrosis-related genes were measured in all animals. Fibrosis-induced rats showed increased hepatic collagen content, reduced MAP, PP, and increased expression of the assessed messengers in comparison with control rats. However, fibrotic rats treated with either AM1241 or F13A had reduced hepatic collagen content, improved MAP and PP, ameliorated cell viability, and reduced angiogenesis and cell infiltrate compared with untreated fibrotic rats. These results were associated with attenuated induction of PDGFR?, ?-SMA, MMPs, and TIMPs. CB2 receptor stimulation or APJ blockade prevents fibrosis progression in CCl4-treated rats. The mechanisms underlying these phenomena are coincident despite the marked dissimilarities between the CB2 and APJ signaling pathways, thus opening new avenues for preventing fibrosis progression in liver diseases. PDGF is the most potent stimulus for proliferation and migration of stellate cells. PDGF receptor ? expression is an important phenotypic change in myofibroblastic cells that mediates proliferation and chemotaxis. Here we analyzed the relationship between PDGFR? expression, hemodynamic deterioration, and fibrosis. Thereafter, we investigated the effects produced by an adenovirus encoding a dominant-negative soluble PDGFR? (sPDGFR?) on hemodynamic parameters, PDGFR? signaling pathway, and fibrosis. Hemodynamics, PDGFR? mRNA expression, and hepatic collagen were assessed in controls and fibrosic/cirrhotic rats. Next, 30 fibrotic rats were randomized into three groups receiving iv saline and an adenovirus encoding for sPDGFR? or ?-galactosidase. After 7days, hemodynamics, serum sPDGFR?, and hepatic collagen were measured. CCl4-treated animals for 18weeks showed a significantly higher increase in PDGFR? mRNA compared to those treated for 13weeks and control rats. In CCl4-treated rats, the fibrous tissue area ranged from moderate to severe fibrosis. A direct relationship between the degree of fibrosis, hemodynamic changes, and PDGFR? expression was observed. Fibrotic rats transduced with the adenovirus encoding sPDGFR? showed increased MAP, decreased PP, lower activation of the PDGFR? signaling pathway, and reduced hepatic collagen than fibrotic rats receiving ?-gal or saline. PDGFR? activation closely correlates with hemodynamic disorders and increased fibrosis in CCl4-treated rats. Adenoviral dominant negative soluble PDGFR? improved fibrosis. As a result, the hemodynamic abnormalities were ameliorated. Cirrhotic patients have altered host-defense response mechanisms. Here we assessed whether impaired expression of CB2 receptor in monocytic cells of cirrhotic patients could be involved in the pathogenesis of this phenomenon. CB2 mRNA and protein expression was assessed in a differentiated human monocytic cell line (U937) stimulated with endotoxin (LPS). A PCR array of 86 different genes was assessed in U937 cells treated with LPS. A migration assay towards endocannabinoids or the CB2 antagonist, SR144528, was performed in U937 cells exposed to LPS. Finally, CB1 and CB2 mRNA expression were measured in monocytes and macrophages of cirrhotic patients with or without spontaneous bacterial peritonitis. LPS reduced CB2 expression in human monocytes. Endocannabinoids increased the migratory activity of U937 cells, which was reverted when the experiments were performed in the presence of LPS. Transcriptional profiling showed marked upregulation of 9 genes related to proinflammatory signaling. However, only two genes encoding for CB1 and CB2 were reduced in LPS-treated cells. Circulating monocytes of cirrhotic patients showed a significantly diminished mRNA expression of CB1 and CB2. Markedly low CB1 and CB2 mRNA levels were found in peritoneal macrophages of cirrhotic patients with ascites, being almost suppressed when analyzed in patients with peritonitis. LPS reduces CB2 expression in human monocytes resulting in depressed chemotactic activity and therefore impaired host defense response of these cells." @default.
• W1447263 created "2016-06-24" @default.
• W1447263 creator A5077440551 @default.
• W1447263 date "2012-12-11" @default.
• W1447263 modified "2023-09-27" @default.
• W1447263 title "Hepatic remodeling, serum biomarkers and prevention of fibrosis progression in liver disease" @default.
• W1447263 hasPublicationYear "2012" @default.
• W1447263 type Work @default.
• W1447263 sameAs 1447263 @default.
• W1447263 citedByCount "0" @default.
• W1447263 crossrefType "dissertation" @default.
• W1447263 hasAuthorship W1447263A5077440551 @default.
• W1447263 hasConcept C102124568 @default.
• W1447263 hasConcept C121608353 @default.
• W1447263 hasConcept C126322002 @default.
• W1447263 hasConcept C134018914 @default.
• W1447263 hasConcept C142724271 @default.
• W1447263 hasConcept C178790620 @default.
• W1447263 hasConcept C185592680 @default.
• W1447263 hasConcept C2777214474 @default.
• W1447263 hasConcept C2777359374 @default.
• W1447263 hasConcept C2778808290 @default.
• W1447263 hasConcept C2779013556 @default.
• W1447263 hasConcept C2779770810 @default.
• W1447263 hasConcept C2780559512 @default.
• W1447263 hasConcept C2780699576 @default.
• W1447263 hasConcept C2781197716 @default.
• W1447263 hasConcept C2993667909 @default.
• W1447263 hasConcept C55493867 @default.
• W1447263 hasConcept C71924100 @default.
• W1447263 hasConceptScore W1447263C102124568 @default.
• W1447263 hasConceptScore W1447263C121608353 @default.
• W1447263 hasConceptScore W1447263C126322002 @default.
• W1447263 hasConceptScore W1447263C134018914 @default.
• W1447263 hasConceptScore W1447263C142724271 @default.
• W1447263 hasConceptScore W1447263C178790620 @default.
• W1447263 hasConceptScore W1447263C185592680 @default.
• W1447263 hasConceptScore W1447263C2777214474 @default.
• W1447263 hasConceptScore W1447263C2777359374 @default.
• W1447263 hasConceptScore W1447263C2778808290 @default.
• W1447263 hasConceptScore W1447263C2779013556 @default.
• W1447263 hasConceptScore W1447263C2779770810 @default.
• W1447263 hasConceptScore W1447263C2780559512 @default.
• W1447263 hasConceptScore W1447263C2780699576 @default.
• W1447263 hasConceptScore W1447263C2781197716 @default.
• W1447263 hasConceptScore W1447263C2993667909 @default.
• W1447263 hasConceptScore W1447263C55493867 @default.
• W1447263 hasConceptScore W1447263C71924100 @default.
• W1447263 hasLocation W14472631 @default.
• W1447263 hasOpenAccess W1447263 @default.
• W1447263 hasPrimaryLocation W14472631 @default.
• W1447263 hasRelatedWork W1148131047 @default.
• W1447263 hasRelatedWork W14616489 @default.
• W1447263 hasRelatedWork W1974115524 @default.
• W1447263 hasRelatedWork W2005574292 @default.
• W1447263 hasRelatedWork W2038536728 @default.
• W1447263 hasRelatedWork W2102358096 @default.
• W1447263 hasRelatedWork W2124773480 @default.
• W1447263 hasRelatedWork W2142307866 @default.
• W1447263 hasRelatedWork W2148795098 @default.
• W1447263 hasRelatedWork W2312643125 @default.
• W1447263 hasRelatedWork W2350184719 @default.
• W1447263 hasRelatedWork W2352884105 @default.
• W1447263 hasRelatedWork W2354882695 @default.
• W1447263 hasRelatedWork W2384599673 @default.
• W1447263 hasRelatedWork W2944347056 @default.
• W1447263 hasRelatedWork W29660629 @default.
• W1447263 hasRelatedWork W3012682946 @default.
• W1447263 hasRelatedWork W3143545527 @default.
• W1447263 hasRelatedWork W3208141666 @default.
• W1447263 hasRelatedWork W3208465440 @default.
• W1447263 isParatext "false" @default.
• W1447263 isRetracted "false" @default.
• W1447263 magId "1447263" @default.
• W1447263 workType "dissertation" @default.